Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab versus placebo in adults with chronic immune thrombocytopenia
NL-OMON58879Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mezagitamab in chronic primary immune thrombocytopenia (ITP), sponsored by Takeda. Started Nov 2025; status: recruiting.
02
Drugs
mezagitamab
03
Conditions
chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON58879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58879.